ReviewParasites & vectors2025
Cyclophilins as key players in protozoan parasite infections.
Review in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophilins (Cyps), a highly conserved family of immunophilins with peptidyl-prolyl cis-trans isomerase (PPIase) activity, play pivotal roles in protein folding, cell signaling, immune modulation, and host-pathogen interactions. In protozoan infections, parasite-encoded Cyps are essential for immune evasion, oxidative stress regulation, and pathogen survival. This review highlights the multifaceted roles of Cyps in Plasmodium, Toxoplasma, Trypanosoma, and Leishmania, with particular emphasis on their involvement in host cell invasion, replication, and immunomodulation. Key Cyps-such as Plasmodium Cyp19B, Toxoplasma Cyp18, Leishmania major Cyp19, and Trypanosoma Cyp19-have been implicated in oxidative stress management, host cell entry, and immune suppression. Given these critical functions, Cyps represent promising therapeutic targets; cyclosporine A (CsA) and its analogs inhibit parasite proliferation by disrupting Cyp activity. Moreover, parasite-derived Cyps show potential as vaccine candidates, eliciting protective immunity in models of leishmaniasis, toxoplasmosis, and Chagas disease. Host Cyps further influence infection outcomes by modulating mitochondrial permeability, cytokine production, and macrophage polarization. For example, mitochondrial CypD regulates cell death pathways in Trypanosoma cruzi-induced cardiac pathology. Despite these advances, further research is required to validate the therapeutic and prophylactic potential of Cyps. Future studies should investigate stage-specific Cyp functions, host-pathogen interactions, and the development of nonimmunosuppressive Cyp inhibitors to advance targeted antiparasitic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.